5 results about "Placental cell" patented technology

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

To provide an improved porcine scaffold comprising decellularized porcine placental extracellular matrix. Further provided are methods of preparing the improved decellularized porcine placental extracellular matrix as well as methods of treatment.SOLUTION: Provided are porcine scaffolds comprising a decellularized porcine placental extracellular matrix, wherein the porcine scaffold comprises at least about 0.5% w / w hyaluronic acid based on the total weight of the porcine scaffold, and methods of preparing the porcine scaffolds.SELECTED DRAWING: Figure 9

The application discloses a kind of based on HAPLN1 down-regulation induced preeclampsia animal model construction method and application of placental cell abnormal aging, belong to the field of biological medicine technology.The application can stably induce the animal model with typical preeclampsia clinical characteristics by reducing the expression level of HAPLN1 in pregnant mice, while reproducing the abnormal phenotype of placental cell aging.The method has strong controllability in operation process, and the model has good reproducibility, which can provide effective experimental tools for in-depth study of the pathogenesis of preeclampsia and development of new diagnosis and treatment strategies.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.